The Case for Moderna and Regeneron: Two Stocks Worth Watching for the Long Haul

Ah, Moderna. You can practically hear the applause still ringing from their meteoric rise during the pandemic. Their mRNA-based COVID-19 vaccine was nothing short of a game-changer, and yes, it made the company a fortune. But with the world finally moving beyond the worst of the pandemic, it’s easy to assume that Moderna’s moment has passed, that the vaccine cash cow has been milked dry. Well, I beg to differ.

🚀 SEC vs. QMMM: The 1,000% Rally That Went *Poof*! 🪙

The SEC, in their infinite wisdom, alleges that this meteoric rise was fueled by anonymous social media promotions. Apparently, someone with a Twitter handle like @CryptoWizard69 whispered sweet nothings about QMMM’s plans to establish a $100 million diversified crypto treasury, complete with investments in Bitcoin, Ethereum (ETH, $4,158, because who’s counting?), and Solana (SOL, $206.6, still cheaper than a night out in London). 📈💸

Unraveling the Energy Transfer Mystery: A Cynic’s Guide

But before you throw your hard-earned doubloons into the Energy Transfer cauldron, take a moment to channel your inner Benjamin Graham – a venerable sage of investment who, as legends tell us, could turn a mundane rock into a desirable asset, provided it was covered with just the right amount of analysis. You may find yourself pondering another contender that has only stumbled half as far, offering a slightly less enthusiastic yield of 6.9%.

Assessing Amazon: A Delicate Dance of Opportunity and Obstacle

This year, Amazon’s ascent appears as sluggish as a bureaucrat slogging through the tedium of paperwork; with a pitiful 0.2% uptick in the ever-engaging 2025, while its lofty counterparts-Alphabet, Nvidia, Netflix, Broadcom, and Oracle-have soared with the grace of white-tailed eagles, each boasting more than a 30% rise. As we take a closer look at Amazon, three reasons may beckon one’s consideration toward its virtues, while two daunting specters linger to whisper caution into the ear of the eager investor.

Republic Bets on Animoca on Solana: A Token Tale

On September 30, Republic proclaimed its plan to tokenize Animoca Brands’ equity, promising global access within a framework that pretends to be compliant. Animoca, a collector of over 600 Web3 investments, brands itself as a maestro who uses tokenization and blockchain to hand over digital property rights to investors, as if ownership could be measured by melody and ledger lines. 😄🪙